Look back at pharma news in the week to March 29

31 March 2019

By Barbara Obstoj-Cardwell. Editor

Among regulatory decisions last week, there was good news for Novartis, with US Food and Drug Administration approval for its multiple sclerosis drug Mayzent, and for AbbVie, which gained clearance in Japan for Skyrizi, which was seen as a bonus for the company as Humira competition looms, On the research front, Galapagos and Gilead Sciences presented positive new Phase III data on their filgotinib in rheumatoid arthritis. Deal-making was also in focus, notably with AstraZeneca acquiring rights to Daiichi Sankyo’s cancer drug candidate trastuzumab deruxtecan.

Novartis wins key US approval for multiple sclerosis drug Mayzent

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK